Retraction: Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia(British Journal of Pharmacology, (2012), 167, (95–108), 10.1111/j.1476-5381.2012.01969.x);Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia

British Journal of Pharmacology

Volumn 167, Issue 1, 2012, Pages 95-108

  Altavilla, D ^a   Minutoli, L ^a   Polito, F ^a   Irrera, N ^a   Arena, S ^a   Magno, C ^a   Rinaldi, M ^a   Burnett, B P ^b   Squadrito, F ^a   Bitto, A ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b PRIMUS PHARMACEUTICALS INC   (United States)

Author keywords

5 LOX; apoptosis; BPH; COX; flavocoxid; growth factors; inflammation

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CASPASE 9; EPIDERMAL GROWTH FACTOR; FLAVOCOXID; ICOSANOID; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; MESSENGER RNA; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FATTY ACID SYNTHESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATIC INFLAMMATORY DISEASE; PROTEIN EXPRESSION; RAT; TISSUE SECTION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84864663685     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.16153     Document Type: Erratum

References (83)

1. Altavilla D, Squadrito F, Bitto A, Polito F, Burnett BP, Di Stefano V, et al,. (2009). Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. Br J Pharmacol 157: 1410-1418.
2. Andrews P, Zhao X, Allen J, Li F, Chang M, (2008). A comparison of the effectiveness of selected non-steroidal anti-infl ammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol 61: 203-214.
3. Arruzazabala ML, Carbajal D, Mas R, Molina V, Rodríguez E, González V, (2004). Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on prostate hyperplasia induced with testosterone in intact and castrated rodents. Drugs Exp Clin Res 30: 227-233.
4. Barry M, Cahill RA, Roche-Nagle G, Neilan TG, Treumann A, Harmey JH, et al,. (2009). Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer. Ir J Med Sci 178: 201-208.
5. Bates DO, Curry FE, (1996). Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol 271: H2520-H2528.
6. van Breemen RB, Sharifi R, Viana M, Pajkovic N, Zhu D, Yuan L, et al,. (2011). Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer Prev Res (Phila) 4: 711-718.
7. Burnett BP, Jia Q, Zhao Y, Levy RM, (2007). A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food 10: 442-451.
8. Burnett BP, Bitto A, Altavilla D, Squadrito F, Levy RM, Pillai L, (2011). Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant. Mediators Inflamm doi:10.1155/2011/385780 [Epub ahead of print].
9. Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, et al,. (2004). Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 10: 6703-6709.
10. Chou TC, Chang LP, Li CY, Wong CS, Yang SP, (2003). The antiinflammatory and analgesic effects of baicalin in carrageenan-evoked thermal hyperalgesia. Anesth Analg 97: 1724-1729.
11. Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, Schiavone N, et al,. (2006). Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 5: 2716-2726.
12. Daniel PT, (2000). Dissecting the pathways to death. Leukemia 14: 2035-2044.
13. De Clerq E, (2005). Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med Res Rev 20: 323-349.
14. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al,. (2002). Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444.
15. Di Silverio F, Bosman C, Salvatori M, Albanesi L, Proietti PL, Pannunzi L, et al,. (2005). Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 47: 72-78.
16. Donnell RF, (2011). Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr Opin Urol 21: 22-26.
17. Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, et al,. (2006). Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 42: 422-426. doi: 10.1016/j.ejca.2005.11.009.
18. Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN, (2008). Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 72: 813-816.
19. FDA Safety Notice (2011). http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258529.htm, Accessed February 5, 2012.
20. Fegn L, Wang Z, (2009). Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. J Laryngol Otol 123: 880-884.
21. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M, (2010). Chronic inflammation in thepathogenesis of benign prostatic hyperplasia. Int J Androl 33: 475-488.
22. Fischer AS, Metzner J, Steinbrink SD, Ulrich S, Angioni C, Geisslinger G, et al,. (2010). 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity. Br J Pharmacol 161: 936-949.
23. Ghosh J, Myers CE, (1998). Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 95: 13182-13187.
24. Golbano JM, Lóppez-Aparicio P, Recio MN, Pérez-Albarsanz MA, (2008). Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. Int J Oncol 32: 919-924.
25. Green DR, Reed JC, (1998). Mitochondria and apoptosis. Science 281: 1309-1312.
26. Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H, (2001). Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 91: 737-743.
27. Han C, Leng J, Demetris AJ, Wu T, (2004). Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 64: 1369-1376.
28. Hilchie AL, Furlong SJ, Sutton K, Richardson A, Robichaud MR, Giacomantonio CA, et al,. (2010). Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria. Nutr Cancer 62: 379-389.
29. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ, (1993). Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251.
30. Huang Y, Tsang SY, Yao X, Chen ZY, (2005). Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 5: 177-184.
31. Itoh N, Patel U, Skinner MK, (1998). Developmental and hormonal regulation of transforming growth factor-alpha and epidermal growth factor receptor gene expression in isolated prostatic epithelial and stromal cells. Endocrinology 139: 1369-1377.
32. Jackson MW, Bentel JM, Tilley WD, (1997). Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 157: 2323-2328.
33. Kang KB, Zhu C, Yong SK, Gao Q, Wong MC, (2009). Enhanced sensitivity of celecoxib in human glioblastoma cells: induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. Mol Cancer 8: 66-81.
34. Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M, (2008). The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 26: 603-609.
35. Kessler OJ, Keisari Y, Servadio C, Abramovici A, (1998). Role of chronic inflammation in the promotion of prostatic hyperplasia in rats. J Urol 159: 1049-1053.
36. Khan N, Adhami VM, Mukhtar H, (2009). Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer 61: 836-841.
37. Kim KS, (2002). Multifunctional role of Fas-associated death domain protein in apoptosis. J Biochem Mol Biol 35: 1-6.
38. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, et al,. (2000). Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56: 671-676.
39. Kramer G, Mitteregger D, Marberger M, (2007). Is benign benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51: 1202.
40. Kumar V, Yadav CS, Datta SK, Singh S, Ahmed RS, Goel S, et al,. (2011). Association of GSTM1 and GSTT1 polymorphism with lipid peroxidation in benign prostate hyperplasia and prostate cancer: a pilot study. Dis Markers 30: 163-169.
41. Larré S, Tran N, Fan C, Hamadeh H, Champigneulles J, Azzouzi R, et al,. (2008). PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat 87: 14-19.
42. Larré S, Camparo P, Comperat E, Boulbés D, Haddoum M, Baulande S, et al,. (2011). Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures. Asian J Androl 14: 499-504.
43. Lee KL, Peehl DM, (2004). Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 172: 1784-1791.
44. Lucia MS, Lambert JR, (2008). Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 9: 272.
45. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M, (2000). Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 130: 641-649.
46. Matsuyama M, Yoshimura R, (2008). The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics 2: 725-732.
47. Matsuyama M, Yoshimura R, Mitsuhashi M, Hase T, Tsuchida K, Takemoto Y, et al,. (2004a). Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int J Oncol 24: 821-827.
48. Matsuyama M, Yoshimura R, Tsuchida K, Takemoto Y, Segawa Y, Shinnka T, et al,. (2004b). Lipoxygenase inhibitors prevent urological cancer cell growth. Int J Mol Med 13: 665-668.
49. McEleny K, Coffey R, Morrissey C, Fitzpatrick JM, Watson RW, (2004). Caffeic acid phenethyl ester-induced PC-3 cell apoptosis is caspase-dependent and mediated through the loss of inhibitors of apoptosis proteins. BJU Int 94: 402-406.
50. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
51. Messina S, Bitto A, Aguennouz M, Mazzeo A, Migliorato A, Polito F, et al,. (2009). Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone. Exp Neurol 220: 349-358.
52. Muralidhar B, Carpenter KL, Müller K, Skepper JN, Arends MJ, (2004). Potency of arachidonic acid in polyunsaturated fatty acid-induced death of human monocyte-macrophages: implications for atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 71: 251-262.
53. Nakanishi Y, Kamijo R, Takizawa K, Hatori M, Nagumo M, (2001). Inhibitors of cyclooxygenase-2 (COX-2) suppressed the proliferation and differentiation of human leukaemia cell lines. Eur J Cancer 37: 1570-1578.
54. Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS, (2003). Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 9: 3503-3513.
55. Narayanan NK, Nargi D, Attur M, Abramson SB, Narayanan BA, (2007). Anticancer effects of licofelone (ML-3000) in prostate cancer cells. Anticancer Res 27: 2393-2402.
56. Nieves D, Moreno JJ, (2006). Role of 5-lipoxygenase pathway in the regulation of RAW 264.7 macrophage proliferation. Biochem Pharmacol 72: 1022-1030.
57. Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, Ambrosetti D, et al,. (2010). Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. Eur J Cancer 46: 3022-3036.
58. Pace G, Di Massimo C, De Amicis D, Corbacelli C, Di Renzo L, Vicentini C, et al,. (2010). Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int 85: 328-333.
59. Pandita RK, Persson K, Hedlund P, Andersson KE, (1998). Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. Prostate 35: 102-108.
60. Pidgeon GP, Kandouz M, Meram A, Honn KV, (2002). Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 62: 2721-2727.
61. Polito F, Bitto A, Irrera N, Squadrito F, Fazzari C, Minutoli L, et al,. (2010). Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis. Br J Pharmacol 161: 1002-1011.
62. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A, (2001). The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8: 11-31.
63. Reed JC, (1995). Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7: 541-546.
64. Revelos K, Petraki C, Gregorakis A, Scorilas A, Papanastasiou P, Koutsilieris M, (2005). Immunohistochemical expression of Bcl-2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 25: 3123-3133.
65. Roehrborn CG, (2011). Male Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH). Med Clin North Am 95: 87.
66. Sarveswaran S, Thamilselvan V, Brodie C, Ghosh J, (2011). Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon. Biochim Biophys Acta 1813: 2108-2117.
67. Schroeder CP, Yang P, Newman RA, Lotan R, (2007). Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol 6: 183-192.
68. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, et al,. (2007). Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52: 964-972.
69. Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S, Toscano V, et al,. (2008). Prostate growth and inflammation. J Steroid Biochem Mol Biol 108: 254-260.
70. Seo YJ, Kim BS, Chun SY, Park YK, Kang KS, Kwon TG, (2011). The apoptotic effect of genistein, biochanin-A and apigenin PC cells was found by p21 through transcriptional inhibition of polo-like kinase-1. J Korean Med Sci 26: 1489-1494.
71. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN, (1998). Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-326.
72. Sumitani K, Kamijo R, Toyoshima T, Nakanishi Y, Takizawa K, Hatori M, et al,. (2001). Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 30: 41-47.
73. Tavolari S, Bonafè M, Marini M, Ferreri C, Bartolini G, Brighenti E, et al,. (2008). Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 29: 371-380.
74. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE, (2007). Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells. Anticancer Drugs 18: 535-541.
75. Tseng-Crank J, Sookyung Sung S, Jia Q, Zhao Y, Burnett BP, Park DR, et al,. (2010). A medicinal plant extract of Scutellaria baicalensis and Acacia catechu reduced lps stimulated gene expression in immune cells: a comprehensive genomic study using qPCR, ELISA, and microarray. J Diet Suppl 7: 253-272.
76. Tsujii M, DuBois RN, (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501.
77. Van Loom IM, (1997). The golden root: clinical applications of Sctellaria baicalensis GEORGI flavonoids as modulators of the inflammatory response. Altern Med Rev 2: 472-480.
78. Wada K, Arita M, Nakajima A, Katayama K, Kudo C, Kamisaki Y, et al,. (2006). Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J 20: 1785-1792.
79. Wang W, Heideman L, Chung CS, Pelling JC, Koehler KJ, Birt DF, (2000). Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 28: 102-110.
80. Xiao X, Wu J, Zhu X, Zhao P, Zhou J, Liu QQ, et al,. (2007). Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 121: 2095-2104.
81. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, Cho CH, (2005). Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26: 827-834.
82. Yoshida T, Shiraishi T, Horinaka M, Nakata S, Yasuda T, Goda AE, et al,. (2007). Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci 98: 1417-1423.
83. Zhou GX, Ding XL, Huang JF, Zhang H, Wu SB, (2007). Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines. Biochim Biophys Acta 1770: 1021-1027.